Graft-Versus-Host Disease (GVHD) Clinical Trials and Research

MSK has many doctors and scientists who are studying the best ways to prevent and treat graft-versus-host disease (GVHD).

Much of this research is focused on methods to prevent GVHD by removing immune cells called T cells from the donor graft — a process known as T cell depletion.

We are also evaluating a number of other approaches, including the use of clinical risk-score for treatment customization and 3D digital photography and reflectance confocal microscopy to evaluate tissues in a noninvasive way.

We are also doing research in the clinic and in the lab in a number of areas including gut tissue regeneration, the microbiota (the community of organisms that live in the body, especially in the gut), and photobiomodulation (a form of light therapy).

Our experts can help determine which clinical trials may be right for you. The following clinical trials for GVHD are currently enrolling new patients. To learn more about a particular study, choose from the list below.

Learn more about clinical trials

and/or
7 Clinical Trials found
A Phase 1 Study of TRX103 in People With Blood Cancers Receiving a Donated Stem Cell Transplant
Graft-versus-host disease (GVHD) is a serious condition that can happen after a stem cell transplant from a donor. The donated cells see the healthy tissues in the recipient's body as foreign and attack them. TRX103 is a new drug designed to reduce the risk of GVHD.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1-2 Study of Belumosudil in Children and Adolescents With Chronic Graft-Versus-Host Disease
Chronic graft-versus-host disease (cGVHD) is a condition in which healthy transplanted stem cells attack the recipient's healthy cells. cGVHD most often happens more than 100 days after a stem cell transplant, but it can happen at any time.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Axatilimab Plus Ruxolitinib in Adults and Children With Chronic Graft-Versus-Host Disease
Researchers want to see if a steroid-free approach using ruxolitinib, with or without axatilimab, works well to treat cGVHD. Ruxolitinib blocks JAK proteins, which may reduce inflammation (swelling) and immune system reactions related to GVHD. Axatilimab blocks a protein called CSF-1R that controls white blood cells which play a role in GVHD.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Belumosudil After a Stem Cell Transplant to Prevent Graft-Versus-Host Disease
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor's healthy immune cells see the recipient's normal cells as foreign and begin to attack them.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Belumosudil in People With Chronic Graft vs. Host Disease
After a stem cell transplant, a condition called chronic graft-versus-host disease (cGVHD) can occur. The new donor immune cells (like T cells and B cells) attack the recipient's healthy tissues, thinking they are foreign. It usually starts around 100 days after the transplant, but it can begin earlier or later.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study Comparing Ruxolitinib/Tacrolimus/Methotrexate with Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease After a Stem Cell Transplant
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor's healthy immune cells see the recipient's normal cells as foreign and attack them.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase II Study of Photobiomodulation Therapy in Children and Adults with Oral Graft-versus-Host Disease after Stem Cell Transplantation
The purpose of this study is to assess the safety and effectiveness of a specialized light treatment for children and adults with chronic graft-versus host disease (GVHD) of the mouth (oral GVHD) that has not improved after standard treatment. GVHD is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body and cause serious health problems. Oral GVHD can cause mouth inflammation, pain, and sores.
New York City, Commack, Basking Ridge, Skin Cancer Center Hauppauge, Westchester, Monmouth, Bergen, Nassau